Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The prevalences of atrial fibrillation (AF) and obesity continue to increase in parallel
News | Atrial Fibrillation
Comparative Study on Dual vs Single Cardioversion for Atrial Fibrillation in Obese Patients

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
Society of NeuroInterventional Surgery issues update to standards and guidelines following research in favor of minimally invasive procedure for deadly type of stroke
News | Stroke
Multiple Randomized Trials Prove More Stroke Patients Can Benefit from Thrombectomy

June 7, 2024 — Access to thrombectomy should be expanded to include patients who experience basilar artery occlusion ...

Home June 07, 2024
Home
Calcific aortic valve disease (CAVD) is the major heart valve disease that afflicts nearly 10 million patients globally
News | Heart Failure
New Study Suggests that Amyloid Contributes to Calcific Aortic Valve Disease Development

June 7, 2024 — Calcific aortic valve disease (CAVD) is the major heart valve disease that afflicts nearly 10 million ...

Home June 07, 2024
Home
Radial artery delivery is a means by which cardiac catheters are advanced through a blood vessel in a patient’s wrist to treat the heart
News | Heart Failure
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

June 7, 2024 —  BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home June 07, 2024
Home
Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3 TAV platform
News | Structural Heart
New Data for Medtronic CoreValve/Evolut TAVR Systems Reinforces Excellent Valve Performance

June 7, 2024 —  Medtronic today announced new data from the CoreValve Evolut Clinical Program, reinforcing the positive ...

Home June 07, 2024
Home
Stuart J. Connolly, MD
Feature | Cardiovascular Business
In Memoriam: Stuart J. Connolly, MD

June 7, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of the ...

Home June 07, 2024
Home
Xylitol is a common zero-calorie sweetener found in sugar-free candy and toothpaste
News | Cardiovascular Clinical Studies
Cleveland Clinic-Led Study Links Sugar Substitute to Increased Risk of Heart Attack and Stroke

June 6, 2024 —Cleveland Clinic researchers found higher amounts of the sugar alcohol xylitol are associated with ...

Home June 06, 2024
Home
Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1
News | Pharmaceuticals
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

June 5, 2024 —  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events.
News | Artificial Intelligence
Landmark Clinical Study in The Lancet Finds New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation at Least 10 Years in Advance

June 4, 2024 — Caristo Diagnostics Limited, a global provider of cardiovascular disease diagnostics and risk prediction ...

Home June 04, 2024
Home
DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months
News | Cardiovascular Clinical Studies
Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES

June 3, 2024 — Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease ...

Home June 03, 2024
Home
Cardiologists performed the fewest biopsies after dual negative HeartCare results compared to single or dual positive results
News | Cardiovascular Clinical Studies
Landmark Study Shows CareDx’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

May 31, 2024 — CareDx, a leading precision medicine company focused on the discovery, development, and commercialization ...

Home May 31, 2024
Home
Elixir Medical recently announced that the PINNACLE I study, evaluating the safety and performance of its LithiX Hertz Contact Intravascular Lithotripsy System (IVL) met its primary safety and effectiveness endpoint of clinical success. Shown here: Elixir Medical CEO Motasim Sirhan.
News | EuroPCR
Elixir Medical PINNACLE I Study of LithiX IVL System Meets Primary Endpoints of Clinical Success

May 30, 2024 — Elixir Medical, a developer of technologies to treat cardiovascular and peripheral disease, announced ...

Home May 30, 2024
Home
New data presented at LINC 2024 support use of thin-strut cobalt chromium stent in calcified iliac lesions
News | Stents Bioresorbable
One-Year BIONETIC-I Study Results Show Safety and Effectiveness of Iliac Artery Treatment With BIOTRONIK’s Dynetic-35 Cobalt Chromium Balloon-Expandable Stent System

May 30, 2024 — Biotronik announced the presentation of the 12-month results from the BIONETIC-I study this week at LINC ...

Home May 30, 2024
Home
Data was presented today byAstraZeneca, at the European Atherosclerosis Society (EAS) Congress in France,on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL-C reduction on top of statin in Phase I trial.
News | Cardiovascular Clinical Studies
Oral PCSK9 Inhibitor Demonstrated Significant LDL-C Reduction on Top of Statin in Phase I Trial Presented at EAS Congress

May 29, 2024 — Data was presented by AstraZeneca on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL ...

Home May 29, 2024
Home
Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1
News | Pharmaceuticals
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA  ...

Home May 24, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now